

# Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective

Rachita Dhurat, MS Sukesh

Department of Dermatology, Lokmanya Tilak Municipal (LTM) Medical College and Hospital, Mumbai, Maharashtra, India

Address for correspondence: Dr. Rachita Dhurat, B 14/2, Maitri Park CHS, Sion, Trombay Road, Chembur, Mumbai - 400 071, Maharashtra, India.

E-mail: rachitadhurat@yahoo.co.in

## ABSTRACT

The utility of platelet-rich plasma (PRP) has spanned various fields of dermatology from chronic ulcer management to trichology and aesthetics, due to its role in wound healing. Though PRP is being used over a long time, there is still confusion over proper terminology to define, classify and describe the different variations of platelet concentrates. There is also a wide variation in the reported protocols for standardization and preparation of PRP, in addition to lack of accurate characterization of the tested products in most articles on the topic. Additionally, the high cost of commercially available PRP kits, precludes its use over a larger population.

In this article, we review the principles and preparation methods of PRP based on available literature and place our perspective in standardizing a safe, simple protocol that can be followed to obtain an optimal consistent platelet yield.

**KEYWORDS:** Platelet-rich plasma, preparation, principles, standardization

## BACKGROUND

Platelets are cytoplasmic fragments of megakaryocytes, formed in the marrow<sup>[1,2]</sup> and approximately 2  $\mu\text{m}$  in diameter. They contain more than 30 bioactive proteins, many of which have a fundamental role in hemostasis or tissue healing.<sup>[3]</sup>

Seven fundamental protein growth factors that are actively secreted by platelet initiate all wound healing process [Table 1].<sup>[4]</sup> PRP also includes three proteins in blood known to act as cell adhesion molecules: Fibrin, fibronectin and vitronectin.<sup>[5]</sup>

Activation causes the granules present in platelets to fuse to its cell membrane (also called degranulation) where the secretory proteins (e.g. PDGF, TGF- $\beta$  etc.)<sup>[6]</sup> are transformed to a bioactive state by the addition of histones and carbohydrate side chains.<sup>[3]</sup> The active proteins are then secreted, binding to transmembrane

receptors of target cells, which include mesenchymal stem cells, osteoblasts, fibroblasts, endothelial cells and epidermal cells. These agonists bound transmembrane receptors then activate an intracellular signal protein that causes the expression of a gene sequence that directs cellular proliferation, matrix formation, osteoid production, collagen synthesis etc. thus provoking tissue repair and tissue regeneration.<sup>[3-8]</sup>

The active secretion of these growth factors by platelets begins within 10 min after activation, with more than 95% of the pre-synthesized growth factors secreted within 1 h.<sup>[9]</sup>

Marx proposed that platelet count of 10 lakh/ml in 5 mL of PRP, as a working definition of PRP, based on the scientific proof of bone and soft tissue healing enhancement.<sup>[9]</sup> There is a scarcity of studies stating the concentration at which optimal stimulation occurs. Rughetti *et al.*<sup>[10]</sup> studied the relationship between the concentration of platelets in platelet gel and changes in the functional activity of human endothelial cells. The proliferation of endothelial cells and its migration and the invasion of endothelial cells occurred in a bell-shaped manner. The authors found that the stimulation for proliferation of endothelial cells peak at  $1.25 \times 10^6$  and angiogenesis at  $1.5 \times 10^6$  platelets/mL, respectively.

### Access this article online

#### Quick Response Code:



Website:  
www.jcasonline.com

DOI:  
10.4103/0974-2077.150734

**Table 1: Platelet growth factors and their specific characteristics<sup>[4]</sup>**

Platelet Growth Factor Type	Growth factor Source	Biological Actions
Platelet derived growth factor (a-b )	Platelets, osteoblasts, endothelial cells, macrophages, monocytes, smooth muscle cells	Mitogenic for mesenchymal cells and osteoblasts, stimulates chemotaxis and mitogenesis in fibroblast/glia/smooth muscle cells, regulates collagenase secretion and collagen synthesis, stimulate macrophage and neutrophil chemotaxis
Transforming growth factor TGF(alpha –beta)	Platelets, extracellular matrix of bone, cartilage matrix, activated TH1 cells and natural killer cells, macrophages/monocytes and neutrophils	Stimulates undifferentiated mesenchymal cell proliferation ; regulates endothelial, fibroblastic and osteoblastic mitogenesis ; regulates collagen synthesis and collagenase secretion, regulates mitogenic effects of growth factors, stimulate endothelial chemotaxis and angiogenesis, inhibits macrophage and lymphocyte proliferation
Vascular endothelial growth factor, VEGF	Platelets, endothelial cells	Increases angiogenesis and vessel permeability, stimulates mitogenesis for endothelial cells
Epidermal growth factor, EGF	Platelets, macrophages, monocytes	Stimulates endothelial chemotaxis / angiogenesis, regulates collagenase secretion, stimulates epithelial /mesenchymal mitogenesis
Fibroblast growth factor, FGF	Platelets, macrophages, mesenchymal cells, chondrocytes, osteoblasts	Promotes growth and differentiation of chondrocytes and osteoblasts, mitogenic for mesenchymal cells, chondrocytes and osteoblasts
Connective tissue growth factor CTGF	Platelets through endocytosis from extracellular environment in bone marrow	Promotes angiogenesis, cartilage regeneration, fibrosis and platelet adhesion
Insulin like growth factor – 1 IGF -1	Plasma, epithelial cells, endothelial cells, fibroblasts, smooth muscle cells, osteoblasts, bone matrix	Chemotaxis for fibroblasts and stimulates protein synthesis. enhances bone formation by proliferation and differentiation of osteoblasts

This signifies the fact that a PRP platelet count 1 million/ mL has become the working definition for therapeutic PRP and also reasons out the criticism on not getting the expected best results of PRP, which might be due to lower concentrations of platelets.

**CLASSIFICATION**

The literature on PRP is considerable, but the published results are often contradictory. It is very difficult to sort and interpret the available data, due to a large number of preparation techniques, terminologies, forms of these materials, and the endless list of potential applications.

According to the classification proposed by Ehrenfest *et al.* (2009), four main families of preparations can be defined, depending on their cell content and fibrin architecture.<sup>[11]</sup>

1. Pure Platelet-Rich Plasma (P-PRP) or leucocyte-poor PRP products are preparations without leucocytes and with a low-density fibrin network after activation.
2. Leucocyte- and PRP (L-PRP) products are preparations with leucocytes and with a low-density fibrin network after activation. It is in this family that the largest number of commercial or experimental systems exist. Particularly, many automated protocols have been developed in the last years, requiring the use of specific kits that allow minimum handling of the blood samples and maximum standardization of the preparations.
3. Pure platelet-rich fibrin (P-PRF) or leucocyte-poor platelet-rich fibrin preparations are without leucocytes and with a high-density fibrin network. These products only exist in a strongly activated gel

form, and cannot be injected or used like traditional fibrin glues.

4. Leucocyte- and platelet-rich fibrin (L-PRF) or second-generation PRP products are preparations with leucocytes and with a high-density fibrin network.

This classification system was largely cited, advocated, and validated by a multi-disciplinary consensus conference published in 2012.<sup>[12]</sup>

**PREPARATION OF PRP**

PRP is obtained from a sample of patients’ blood drawn at the time of treatment. A 30 cc venous blood draw will yield 3-5 cc of PRP depending on the baseline platelet count of an individual, the device used, and the technique employed. The blood draw occurs with the addition of an anticoagulant, such as citrate dextrose A to prevent platelet activation prior to its use. The authors employ a specialized ‘table top cold centrifuge’ device. Preparation-related costs are significantly lower than with commercial kits.

**PRINCIPLES OF PRP PREPARATION**

PRP is prepared by a process known as differential centrifugation. In differential centrifugation, acceleration force is adjusted to sediment certain cellular constituents based on different specific gravity.

There are many ways of preparing PRP. It can be prepared by the PRP method or by the buffy-coat method.

In the PRP method, an initial centrifugation to separate red blood cells (RBC) is followed by a second centrifugation to concentrate platelets, which are

suspended in the smallest final plasma volume. In Figure 1, flow chart describes a double centrifugation process of PRP. WB (whole blood) is initially collected in tubes that contain anticoagulants. The first spin step is performed at constant acceleration to separate RBCs from the remaining WB volume. After the first spin step, the WB separates into three layers: an upper layer that contains mostly platelets and WBC, an intermediate thin layer that is known as the buffy coat and that is rich in WBCs, and a bottom layer that consists mostly of RBCs. For the production of pure PRP (P-PRP), upper layer and superficial buffy coat are transferred to an empty sterile tube. For the production of leucocyte rich PRP (L-PRP), the entire layer of buffy coat and few RBCs are transferred. The second spin step is then performed. 'g' for second spin should be just adequate to aid in formation of soft pellets (erythrocyte-platelet) at the bottom of the tube. The upper portion of the volume that is composed mostly of PPP (platelet-poor plasma) is removed. Pellets are homogenized in lower 1/3rd (5 ml of plasma) to create the PRP (Platelet-Rich Plasma).

In the buffy coat method, whole blood (WB) is centrifuged at a 'high speed' with subsequent collection of the buffy coat. A buffy coat contains high concentration of leucocytes.

From small volume of WB (10 mL), a very thin layer of a buffy coat can be produced. The difficulty lies in separating this thin buffy coat layer that contains

mainly white blood cells (WBCs) and platelets, from the underlying RBC layer.

### Procedure<sup>[13,14]</sup>

#### PRP method

1. Obtain WB by venipuncture in acid citrate dextrose (ACD) tubes
2. Do not chill the blood at any time before or during platelet separation.
3. Centrifuge the blood using a 'soft' spin.
4. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).
5. Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.
6. The lower 1/3<sup>rd</sup> is PRP and upper 2/3<sup>rd</sup> is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.
7. Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube.

#### Buffy coat method

1. WB should be stored at 20°C to 24°C before centrifugation.
2. Centrifuge WB at a 'high' speed.
3. Three layers are formed because of its density: The bottom layer consisting of RBCs, the middle layer consisting of platelets and WBCs and the top PPP layer.
4. Remove supernatant plasma from the top of the container.
5. Transfer the buffy-coat layer to another sterile tube.
6. Centrifuge at low speed to separate WBCs or use leucocyte filtration filter.

There is no consensus on whether or not platelets must be previously activated before their application and with which agonist. Some authors activate platelets with thrombin or calcium, whereas others apply platelets without being previously activated, arguing that better results are obtained.<sup>[15]</sup>

### COMMERCIALY AVAILABLE PRP KITS

There are many PRP systems commercially marketed, which facilitate the preparation of ready to apply platelet-rich suspensions in a reproducible manner. All operate on a small volume of drawn blood (20-60 mL) and on the principle of centrifugation. These systems differ widely in their ability to collect and concentrate platelets depending on the method and time of its centrifugation. As a result, suspensions of different concentration of platelets and leucocytes are obtained. Differences in the concentrations in platelets and WBCs influence the diversity of growth factors concentration. It is difficult to assess which kit for PRP preparation is better and which is worse.




Figure 1: Flowchart describing preparation of PRP

PRP devices can be usually divided into lower (2.5-3 times baseline concentration) and higher (5-9 times baseline concentration) systems. The high-yielding devices include Biomet GPS II and III (platelet count 3-8×); Harvest SmartPRep 2 APC+ (4-6×); ArterioCyte-Medtronic Magellan (3-7×). The lower concentration systems include Arthrex ACP (2-3×), Cascade PPR therapy (1-1.5×), and PRGF by Boitech Institute Vitoria, Spain (2-3×). Regen PRP (Regen Laboratory, Mollens, Switzerland).<sup>[6,16-19]</sup>

**COMPARISON OF STUDIES OF PREPARATION**

PRP is prepared by centrifugation varying the relative centrifugal force, temperature and time. It has been seen that the two-step procedure renders the highest output.

Preparation procedures are also relevant, as shown by studies of the chondro-inductive and osteo-inductive potential of PRP.<sup>[20]</sup>

There are numerous protocols in the current literature that describe the optimal conditions for centrifugation [Table 2]. However, these various protocols have been optimized with respect to different variables of the process, such as volume and sampling of processed WB, number of spins, time period of centrifugation, and range of centrifugal acceleration. Considering the complexity of an autologous product such as PRP and the need for quality control in clinical applications, it is crucial to demonstrate procedure’s ability to reproduce consistent results.

Despite these variations, all protocols follow a generic sequence that consists of blood collection, an initial centrifugation to separate RBCs, subsequent centrifugations to concentrate platelets, and other components and an activation of the sample by adding a platelet agonist.

Amable *et al.*<sup>[21]</sup> studied variations in relative centrifugal force (RCF), temperature, and time for optimizing conditions for platelet isolation and quantification of cytokines and growth factors in PRP before and after platelet activation.

Peripheral blood from 22 healthy male and female volunteer donors (20-54 years old) was collected using 4.5 mL blood collection tubes containing 0.5 mL citrate solution (VacutainerW, Ref: 369714; BD Biosciences). Blood samples were run by choosing RCF from 240 to 400×g, time from 8 to 19 min and temperature from 8° to 16°C. All steps were performed in a refrigerated centrifuge (certified Jouan Br4i, Saint-Herblain, Loire-Atlantique, France).

The best performance was obtained using parameters of 300×g for 5 min at 12°C and 240×g for 8 min at 16°C for 1<sup>st</sup> spin. The second spin of 700 × g for 17 min was chosen since it allowed a lower platelet loss into the PPP fraction and produced a pellet that was easily resuspended.<sup>[21]</sup>

Amanda *et al.*<sup>[22]</sup> demonstrated that the processing of 3.5 mL of blood at 100×g for 10 min (1<sup>st</sup> spin), 400×g for 10 min (2<sup>nd</sup> spin) and withdrawing 2/3 of remnant plasma, promoted high platelet recovery (70%-80%) and concentration (5×) maintaining platelet integrity and viability. Authors believe that time and acceleration are the fundamental parameters that define the composition of the PRP sample after the first spin step. Longer time periods slightly increased platelet recovery and decreased the concentrations of WBC in the upper layer. Therefore, time could be a control parameter when low levels of WBC, such as granulocytes and lymphocytes, are required in the PRP sample.

Various factors contribute to platelet concentration gradient such as the size of platelets, the biological difference among individuals and hematocrit variability.

**Table 2: Comparison of various protocols for platelet yield**

Study	Volume of WB (mL)	1 <sup>st</sup> Centrifugation		2 <sup>nd</sup> Centrifugation		Platelet count rise
		Force (RCF)	Time (min)	Force (RCF)	Time (min)	
Amable <i>et al.</i>	4.5	300	5	700	17	1.4×10 <sup>6</sup> to 1.9×10 <sup>6</sup> 5.4-fold to 7.3-fold
Amanda <i>et al.</i>	3.5	100	10	400	10	1.222±166×10 <sup>3</sup> 5-fold
Khan <i>et al.</i>	478	3731	4	—	—	8.3×10 <sup>10</sup>
Slichter and Harker	250-450	1000	9	3000	20	80% Recovery
Landesberg <i>et al.</i>	5	200	10	200	10	5.57 to 9.35×10 <sup>8</sup>
Jo <i>et al.</i>	9	900	5	1500	15	633.2±91.6×10 <sup>3</sup> 4.2 times
Bausset	10	250	15	250	15	3.96 times
Tamimi <i>et al.</i>	8.5	160	10	400	10	630.2×10 <sup>3</sup>
Mazzocca <i>et al.</i>	27	1500 rpm	5	6300 rpm	20	472×10 <sup>3</sup>
Anitua <i>et al.</i>	4.5	460	8	Single spin only		2.67 times
Araki <i>et al.</i>	7.5	270	10	2300	10	189.6×10 <sup>4</sup>
Kececi <i>et al.</i>	9	250	10	750	10	679.9×10 <sup>3</sup>

RCF: Relative centrifugal force, WB: Whole blood

However, this gradient is more critical after the second spin step because some erythrocytes are inevitably present in the volume that was transferred from the first spin. The presence of these remaining RBCs can generate a pellet at the bottom of the tube, which adsorb platelets and WBCs on its surface. The manual mixing for a short period of time is insufficient to completely resuspend the platelets, and a large variability in platelet counting is observed. Approximately 20% of platelets remained adsorbed in the RBC pellet.<sup>[22]</sup>

Kahn *et al.*<sup>[23]</sup> determined that a centrifugal acceleration of  $3731 \times g$  for a period of 4 min was the optimal condition for obtaining the highest platelet concentration from 478 mL of WB.

The highest platelet recovery efficiency obtained by Slichter and Harker<sup>[24]</sup> was 80%, using a sample of 250-450 mL of WB centrifuged at  $1000 \times g$  for a period of 9 min. It was observed that a subsequent centrifugation step of  $3000 \times g$  for a period of 20 min decreased the platelet viability.

Landesberg *et al.* obtained PRP samples that had approximately 3.2 times the concentration of the WB baseline. The centrifugation procedure processed 5 mL of WB for two spins at  $200 \times g$  for 10 min per spin.<sup>[25]</sup>

Jo *et al.* examined the effect of the centrifugation time and gravitational force ( $g$ ) on the platelet recovery ratio of PRP. Two-step centrifugations for preparing PRP were used in 39 subjects. WB was centrifuged from  $500 \times g$  to  $1900 \times g$  at  $200 \times g$  increments for 5 min and from  $100 \times g$  to  $1300 \times g$  at  $200 \times g$  increments for 10 min. In the step 2, platelets in the separated plasma were concentrated at  $1000 \times g$  for 15 min,  $1500 \times g$  for 15 min,  $2000 \times g$  for 5 min and  $3000 \times g$  for 5 min. They achieved better efficiency (92%) by applying an acceleration of  $900 \times g$  for 5 min for the first spin step. A total of 9 mL of WB were processed, and the platelet concentration was measured to be  $310.7 \pm 78.5 \times 10^3/\text{mm}^3$ . The maximum efficiency for the second spin step (84%) was obtained by applying  $1500 \times g$  for 15 min. The platelet concentration was  $633.2 \pm 91.6 \times 10^3/\text{mm}^3$ , which was 4.2 times greater than the baseline concentration.<sup>[26]</sup>

Bausset *et al.* found that a centrifugation of  $130 \times g$  or  $250 \times g$  for a period of 15 min was optimal when performing a procedure that involved two spins. A platelet concentration factor of 3.47 was obtained from the 8.5 mL WB processed, and 2.0 mL of plasma was processed in the second spin step.<sup>[27]</sup>

Tamimi *et al.*<sup>[28]</sup> compared two methods for obtaining PRP: Double centrifugation (ACE system; Surgical Supply and Surgical Science Systems, Brockton, MA,

USA) and single centrifugation (Nahita System; Nahita, Navarra, Spain). Three test tubes of 8.5 mL WB each were introduced into an ACE centrifuge machine and subjected to a force of  $160 \times g$  (1300 rpm) for 10 min. For second centrifugation,  $400 \times g$  force (2000 rpm) for 10 min was applied. For Nahita system blood was extracted into 3.5-mL citrated tubes (Venojet; Terumo MR, Tokyo, Japan) containing 0.5 mL of trisodium citrate, citrate, and ACD as anticoagulants. Test tubes were centrifuged with a  $280 \times g$  force (1500 rpm) for 7 min. Platelet concentration from the ACE and Nahita systems were (336%) and (227%), respectively.

Mazzocca *et al.*<sup>[29]</sup> analyzed three protocols for preparing PRP samples with different compositions: A low platelet ( $382 \times 10^3/\text{mm}^3$ ) and low WBC ( $0.6 \times 10^3/\text{mm}^3$ ) process with one spin step at 1500 rpm for 5 min (10 mL WB); a high platelet ( $940 \times 10^3/\text{mm}^3$ ) and high WBC ( $17 \times 10^3/\text{mm}^3$ ) process with one spin step at 3200 rpm for 15 min (27 mL WB); and a double-spin process (1500 rpm for 5 min and 6300 rpm for 20 min) that produced a higher platelet concentration ( $472 \times 10^3/\text{mm}^3$ ) and lower WBC ( $1.5 \times 10^3/\text{mm}^3$ ).

Anitua *et al.*<sup>[30]</sup> used only one centrifugation spin step and collected the volume immediately above the erythrocyte layer. Blood was collected on sterile tubes (4.5 mL) containing 3.8% (w/v) trisodium citrate, then centrifuged at  $460 \times g$  for 8 min (PRGF System1, B.T.I. Biotechnology Institute, Vitoria-Gasteiz, Spain). This protocol obtained a platelet concentration factor of 2.67 above the baseline value.

Dugrillon *et al.*<sup>[31]</sup> reported that the number of platelets is not always proportional to the growth factors' quantity, so more attention should be given to the quality of PRP than to the number of platelets concentrated. Their study proved that the TGF- $\beta$ 1 and platelet concentration are proportionally related to the centrifugation forces when the forces are less than  $800 \times g$ . TGF- $\beta$ 1 becomes inversely related to the centrifugal force when forces are above  $800 \times g$ .

Araki *et al.*<sup>[32]</sup> concluded that optimized protocol for PRP preparation was centrifugation of WB at  $230$ - $270 \times g$  for 10 min, which also contained a low number of WBCs (4.1%-5.8% of WB). WBCs appeared to be precipitated when the centrifugation force was  $\geq 840 \times g$ .

In their protocol, WB (40-72 mL) was drawn by venipuncture, collected, and divided into 7.5-mL aliquots in 15-mL conical tubes and centrifuged conical tubes (15 mL; BD Falcon). Tubes were centrifuged at  $20^\circ\text{C}$  in a refrigerated centrifuge (Kubota 5900; Kubota Co.). For the second spin step, an acceleration of  $2300 \times g$  for 10 min was applied. The platelet concentration factor was 7.4 times

greater than the baseline after removing approximately 1/10 of the PPP and adding ethylenediaminetetraacetic acid (EDTA) as an anticoagulant.

Many other studies<sup>[33,34]</sup> specified centrifugal accelerations in rotations per minute (rpm) instead of in  $\times g$ , complicating the task of comparing and reproducing their results.

In a recent study by Kececi *et al.*,<sup>[35]</sup> the first spin (soft spin) protocol was chosen as 250–270 $\times g$  for 10 min. At the second spin, centrifugation force was varied from 300 $\times g$ , 500 $\times g$ , 750 $\times g$ , 1000 $\times g$ , 1500 $\times g$  and 2000 $\times g$  for 10 min. The platelet concentration factor increased as the centrifugal force of the second spin increased as 1.92-fold, 2.16-fold, 2.80-fold, 3.48-fold, 3.67-fold, and 3.76-fold after a 10-min second centrifugation at 300 $\times g$ , 500 $\times g$ , 750 $\times g$ , 1000 $\times g$ , 1500 $\times g$  and 2000 $\times g$ , respectively. The authors opined that obtaining a definite platelet concentration might be possible by adjusting centrifugation force individually according to the personal baseline value.

### AUTHORS' PERSPECTIVE

There are various protocols described in the literature for preparation of PRP. Centrifugal acceleration, number of spins, time and distance between the particles and the rotor to the volume of processed WB are critical for optimization of PRP. Each laboratory must standardize its protocol. A handmade standard PRP could be prepared reliably and cost effectively without using a commercial kit. The platelet concentration factor can be changed with the centrifugation force applied in PRP preparation.

### Factors influencing PRP yield

Various factors influence the yield of PRP such as draw of blood; speed, time and temperature of centrifugation and use of anticoagulants.

#### Draw of blood

The clotting process is influenced from the time of the draw. To avoid unintentional activation of platelets, most protocols use large bore needles (>22) to draw the blood.<sup>[17]</sup>

In a study by Waters and Roberts,<sup>[18]</sup> using two cell-salvage devices and two table top devices over the course of 260 clinical cases, they found that there was a downward trend in platelet counts with longer draw time.

#### Centrifugation

The earth's gravitational force is sufficient to separate many types of particles over time. A tube of anti-coagulated WB left standing on a bench top will eventually separate into plasma, RBC and WBC

fractions. However, the length of time required precludes this manner of separation for most applications. In addition, the potential degradation of biological compounds during prolonged storage means faster separation techniques are needed. Hence, to accelerate sedimentation, the effect of gravity is amplified using 'centrifugal force' provided by a centrifuge and can be many thousand times the force of gravity.

Separation of cellular constituents within blood can be achieved by a process known as differential centrifugation. In differential centrifugation, acceleration force is adjusted to sediment certain cellular constituents and leave others in suspension. In centrifugation, RCF is the force required to separate two phases, this force also called relative centrifugal field.

It is expressed as multiples of the earth's gravitational field (g). By accelerating the g, speedy sedimentation can be achieved.

'g' is the actual force exerted on the contents of the spinning rotor, which separates the aqueous solutions in the centrifuge. Revolutions per minute (rpm) is calculated using the following equation.<sup>[36]</sup>

#### Formula

$$g = (1.118 \times 10^{-5}) R S^2$$

Where 'g' is the RCF, R is the radius of the rotor (from centre of rotor to sample) in centimetres and S is the speed of the centrifuge in revolutions per minute.

It is important to remember that calculation of RCF is dependent on the radius of the centrifuge rotor used. The same centrifuge machine with different rotors can produce different acceleration forces.

#### Temperature

Temperature during processing is crucial to prevent platelet activation. AABB manual recommends 21°C–24°C for centrifugation of blood for obtaining PRP.<sup>[13]</sup>

Macey *et al.*<sup>[37]</sup> also stated that cooling may retard platelet activation and this may be essential in obtaining PRP with viable platelets.

Many authors have used a temperature level of 12°C–16°C during centrifugation for best platelet recovery.

This is germane to those who use an ordinary centrifuge to develop PRP, which are mainly developed for diagnostic purposes and not for PRP processing and hence may not produce a sufficient platelet yield.

**Anticoagulants**

The importance lies in choosing an anticoagulant capable of preserving the platelets’ best possible functionality, integrity, and morphology.

With regard to the type of anticoagulant for use, most authors agree on not using EDTA because it could damage the platelet membrane. Therefore, anticoagulants with citrate and dextrose or sodium citrate are recommended.<sup>[38]</sup>

The authors compared the effects of sodium citrate and ACD-A on platelet aggregation, pH and extracellular iCa concentration. The anticoagulant ACD-A is the choice for collection of platelets by apheresis, whereas trisodium citrate (3.2% or 3.8%) is the anticoagulant most commonly used for diagnostic evaluations of platelets. Trisodium citrate and ACD-A solutions differ markedly in pH, with ACD-A having a pH of 4.9 and 3.8% sodium citrate having a pH of 7.8. In addition, the citrate ion concentration in ACD-A is 15.6 mg/mL, whereas 3.8% sodium citrate contains 24.4 mg of citrate ion/mL. It has been reported. In several species that alterations in the pH and extracellular iCa concentration of PRP can affect platelet aggregation in vitro, with aggregation typically impaired at acidic pH and lower extracellular iCa concentrations.<sup>[39,40]</sup>

Alternatively citrate phosphate dextrose-adenine) can be used. It is similar to ACD-A but has fewer supportive ingredients and, therefore, is 10% less effective in maintaining platelet viability.<sup>[9]</sup>

**Activation of PRP**

PRP activation prior to injection is another parameter that requires further discussion. PRP can be activated exogenously by thrombin, calcium chloride or mechanical trauma. Collagen is a natural activator of PRP, thus

when PRP is used in soft tissue, it does not need to be exogenously activated.<sup>[17]</sup>

Once PRP is activated, (fibrinogen-fibrin) a fibrin network begins to form, solidifying the plasma and creating a fibrin clot or membrane.

According to Weibrich *et al.*,<sup>[41]</sup> there are no significant changes in the platelet concentration or on the concentration of growth factors in relation to age and gender, although there are studies that report that the hematocrit and total platelet count influence the platelet concentration of the PRP.<sup>[42]</sup>

**HELPFUL TIPS FOR STANDARDIZATION OF PRP PROCEDURE**

The clinician needs to determine how much PRP he would need to generate for the particular procedure.

As previously stated, many factors influence PRP yield. The following points are helpful in obtaining an optimum PRP concentrate.

1. Draw blood in anticoagulant vacutainer tubes using BD Eclipse™ blood collection needle (Ref: 368607; BD Biosciences, India) [Figure 2]. Set apart 1-2 mL for baseline cell counting including RBCs, platelets, WBCs and hematocrit. Donor percent hematocrit (the ratio of the volume of RBCs to the total volume of blood) is relevant to plasma yield optimization. Blood with a low percent hematocrit has more plasma available thereby diluting the concentration of platelets in plasma.
2. Blood samples that are collected in ACD tubes should be inverted 5-10 times for proper mixing of the anticoagulant and blood. If the tube is not mixed, small fibrin clots may form, causing a falsely decreased platelet count.



Figure 2: Venipuncture using BD Eclipse™ blood collection needle

ID. AKRT19009PRP3ml Date 2014/11/20 Time 19:36 Mode WB		ID. ARC-P Date 2014/10/29 Time 17:53 Mode WB	
WBC	3.0 ×10 <sup>9</sup> /μL	WBC	7.0 ×10 <sup>9</sup> /μL
RBC	! 0.04 ×10 <sup>9</sup> /μL	RBC	! 0.12 ×10 <sup>9</sup> /μL
HGB	! 0.0 g/dL	HGB	- 0.1 g/dL
HCT	! 0.2 %	HCT	! 0.5 %
MCV	---- - fL	MCV	---- - fL
MCH	---- - pG	MCH	---- - pG
MCHC	---- - g/dL	MCHC	---- - g/dL
PLT	! 1594 ×10 <sup>9</sup> /μL	PLT	AG! 1217 ×10 <sup>9</sup> /μL
ID. 5 Date 2014/12/12 Time 19:16 Mode WB		ID. 14 Date 2014/11/05 Time 21:45 Mode WB	
WBC	11.3 ×10 <sup>9</sup> /μL	WBC	4.3 ×10 <sup>9</sup> /μL
RBC	! 0.11 ×10 <sup>9</sup> /μL	RBC	! 0.11 ×10 <sup>9</sup> /μL
HGB	- 0.1 g/dL	HGB	! 0.0 g/dL
HCT	! 0.4 %	HCT	! 0.4 %
MCV	---- - fL	MCV	---- - fL
MCH	---- - pG	MCH	---- - pG
MCHC	---- - g/dL	MCHC	---- - g/dL
PLT	AG! 1577 ×10 <sup>9</sup> /μL	PLT	AG! 1804 ×10 <sup>9</sup> /μL

Figure 3: Consistency of PRP yield

3. After 1<sup>st</sup> spin, measure the platelet count in RBCs and the supernatant to ensure optimal separation of platelets from the WB.
4. If this does not happen, change the parameters like rpm and time.
5. After first spin, if large volume of plasma is obtained, then it would need higher 'g' to concentrate platelets at the bottom of the tube (law of velocity).
6. After 2<sup>nd</sup> spin, measure the platelet count in PPP and PRP after adequately racking the tubes.
7. If higher concentration of platelets in platelet poor plasma (upper layer) or lower concentration in PRP (bottom layer) is observed, then the parameters are not optimal.
8. PRP must be separated from the PPP soon after centrifugation because the concentrated platelets will slowly diffuse into the PPP over time and would reduce the platelet count of the PRP preparation.<sup>[3]</sup>
9. For counting the platelets in the final PRP concentrate, it must be re-suspended for at least 5-10 min to allow for equal distribution of platelets before counting.<sup>[31]</sup>

To obtain a yield of platelet in PRP more than 10 lakhs/mL, all variables like rpm, time and temperature should be standardized and also consistency of platelet concentrate has to be maintained over the period. After several attempts with various permutations & combinations, the authors found that at 900g x 5 mins for 1st centrifugation and 1000g x 10 mins for 2nd centrifugation at 16° C in a refrigerated centrifuge (RemiCM8plus; Remiworld, India), the PRP yield was found to be optimum. Authors have consistently recorded platelet count exceeding 10 lakhs/ml using these parameters [Figure 3].

## CONCLUSION

The utility of PRP is increasing in the field of dermatology and aesthetics. Though commercially marketed PRP systems offer ready-to-apply platelet-rich suspensions in a sterile manner, high cost, limited volume of drawn blood, differences in centrifugation guidelines, wide variation in platelet concentration, makes it difficult for the clinician to choose amongst the readily available PRP kits.

There are many protocols for preparation of PRP each having its own standardized parameters and claimed results, as mentioned in the review. It is advisable to standardize individual preparation protocols, which are cost-effective and easy to adapt in clinical settings.

Understanding of basic principles of centrifugation is of paramount importance in preparation of PRP. Repeated methodology trials by 'trial and error approach', strict

vigilance at maintaining sterility and regular cross-checking of the platelet values are a must to obtain consistent results.

## REFERENCES

1. Conley CL. Hemostasis. In: Mountcastle VB, editor. Medical Physiology. St. Louis: The C.V. Mosby Company; 2004. p. 1137-46.
2. Harrison P, Cramer EM. Platelet alpha-granules. *Blood Rev* 1993;7:52-62.
3. Schliephake H. Bone growth factors in maxillofacial skeletal reconstruction. *Int J Oral Maxillofac Surg* 2002;31:469-84.
4. Sunitha Raja V, Munirathnam Naidu E. Platelet-rich fibrin: Evolution of a second-generation platelet concentrate. *Indian J Dent Res* 2008;19:42-6.
5. Cole BJ, Seroyer ST, Filardo G, Bajaj S, Fortier LA. Platelet-rich plasma: Where are we now and where are we going? *Sports Health* 2010; 2:203-10.
6. Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. *J Extra Corpor Technol* 2004;36:28-35.
7. Marx RE. Platelet-rich plasma: Evidence to support its use. *J Oral Maxillofac Surg* 2004;62:489-96.
8. Antoniades HN, Williams LT. Human platelet-derived growth factor: Structure and functions. *Fed Proc* 1983;42:2630-4.
9. Marx RE. Platelet-rich plasma (PRP): What Is PRP and What Is Not PRP? *Implant Dent* 2001;10:225-8.
10. Rughetti A, Giusti I, D'Ascenzo S, Leocata P, Carta G, Pavan A, *et al.* Platelet gel-released supernatant modulates the angiogenic capability of human endothelial cells. *Blood Transfus* 2008;6:12-7.
11. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol* 2009;27:158-67.
12. Dohan Ehrenfest DM, Bielecki T, Mishra A, Borzini P, Inchingolo F, Sammartino G, *et al.* In search of a consensus terminology in the field of platelet concentrates for surgical use: Platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. *Curr Pharm Biotechnol* 2012;13:1131-7.
13. Sweeny J, Grossman BJ. Blood collection, storage and component preparation methods. In: Brecher M, editor. *Technical Manual*. 14th ed. Bethesda MD: American Association of Blood Banks (AABB) 2002;955-8.
14. Welsh WJ. Autologous platelet gel: Clinical function and usage in plastic surgery. *Cosmetic Derm* 2000;11:13-9.
15. Scherer SS, Tobalem M, Vigato E, Heit Y, Modarressi A, Hinz B, *et al.* Non-activated versus thrombin-activated platelets on wound healing and fibroblast-to-myofibroblast differentiation *in vivo* and *in vitro*. *Plast Reconstr Surg* 2012;129:46e-54e.
16. Platelet Rich Plasma (PRP) Guidelines, © International Cellular Medicine Society - 2011. Available from: <http://www.cellmedicinesociety.org>. [Last accessed 2014 Dec 5].
17. Marlovits S, Mousavi M, Gabler C, Erdös J, Vécsei V, *et al.* A newsimplified technique for producing platelet-rich plasma: A short technical note. *Eur Spine J* 13:102-06.
18. Waters JH, Roberts KC. Database review of possible factors influencing point-of-care platelet gel manufacture. *J Extra Corpor Technol* 2004;36:250-4.
19. Lozada JL, Caplanis N, Proussaefs P, Willardsen J, Kammeyer G. Platelet-rich plasma application in sinus graft surgery: Part I--background and processing techniques. *J Oral Implantol* 2001;27:38-42.
20. Han B, Woodell-May J, Ponticciello M, Yang Z, Nimni M. The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity. *J Bone Joint Surg Am* 2009;91:1459-70.
21. Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, Corrêa do Amaral RJ, Granjeiro JM, *et al.* Platelet-rich plasma preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors. *Stem Cell Res Ther* 2013;4:67.



22. Perez AG, Lana JF, Rodríguez AA, Luzo AC, Belangero WD, Santana MH. Relevant aspects of centrifugation step in the preparation of platelet-rich plasma. *ISRN Hematol* 2014;2014:176060.
23. Kahn RA, Cossette I, Friedman LI. Optimum centrifugation conditions for the preparation of platelet and plasma products. *Transfusion* 1976;16:162-5.
24. Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. *Br J Haematol* 1976;34:395-402.
25. Landesberg R, Roy M, Glickman RS. Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. *J Oral Maxillofac Surg* 2000;58:297-301.
26. Jo CH, Roh YH, Kim JE, Shin S, Yoon KS. Optimizing platelet-rich plasma gel formation by varying time and gravitational forces during centrifugation. *J Oral Implantol* 2013;39:525-32.
27. Bausset O, Giraudo L, Veran J, Magalon J, Coudreuse JM, Magalon G, *et al.* Formulation and storage of platelet-rich plasma homemade product. *Biores Open Access* 2012;1:115-23.
28. Montalvo S, Tresguerres I, Tamini FM, Blanco Jerez L. A comparative study of 2 methods for obtaining platelet rich plasma. *J Oral Maxillofac Surg* 2007;65:1084-93.
29. Mazzocca AD, McCarthy MB, Chowaniec DM, Cote MP, Romeo AA, Bradley JP, *et al.* Platelet-rich plasma differs according to preparation method and human variability. *J Bone Joint Surg Am* 2012;94:308-16.
30. Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezal A, Orive G, *et al.* Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. *J Biomed Mater Res B Appl Biomater* 2008;84:415-21.
31. Dugrillon A, Eichler H, Kern S, Klüter H. Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration. *Int J Oral Maxillofac Surg* 2002;31:615-9.
32. Araki J, Jona M, Eto H, Aoi N, Kato H, Suga H, *et al.* Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: Maximization of platelet concentration and removal of fibrinogen. *Tissue Eng Part C Methods* 2012;18:176-85.
33. Fernández-Barbero JE, Galindo-Moreno P, Ávila-Ortiz G, Caba O, Sánchez-Fernández E, Wang HL. Flow cytometric and morphological characterization of platelet-rich plasma gel. *Clin Oral Implants Res* 2006;17:687-93.
34. Su CY, Kuo YP, Nieh HL, Tseng YH, Burnouf T. Quantitative assessment of the kinetics of growth factors release from platelet gel. *Transfusion* 2008;48:2414-20.
35. Kececi Y, Ozsu S, Bilgir O. A cost-effective method for obtaining standard platelet-rich plasma. *WOUNDS* 2014;26:232-8.
36. Bentley's textbook of pharmaceuticals -An update, Sanjay Kumar Jain, Vandana Soni, 1st edition, 2014; Chapter 17:556-65.
37. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, *et al.* Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. *Clin Chem* 2002;48:891-9.
38. Anitua E, Prado R, Sánchez M, Orive G. Platelet-rich-plasma: Preparation and formulation. *Oper Tech Orthop* 2012;22:25-32.
39. Callan MB, Shofer FS, Catalfamo JL. Effects of anticoagulant on pH, ionized calcium concentration, and agonist-induced platelet aggregation in canine platelet-rich plasma. *American journal of veterinary research* 2009;70:472-7. doi:10.2460/ajvr.70.4.472.
40. Guder WG, Narayanan S, Wisser H, Zawta B. Special Aspects of Haematological Analysis: Diagnostic Samples: From the Patient to the Laboratory: The Impact of Preanalytical Variables on the Quality of Laboratory Results. 4<sup>th</sup> ed. Wiley – Blackwell Publications, 2009; pg. 36-7.
41. Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. *Bone* 2004;34:665-71.
42. Woodell-May JE, Ridderman DN, Swift MJ, Higgins J. Producing accurate platelet counts for platelet rich plasma: Validation of a hematology analyzer and preparation techniques for counting. *J Craniofac Surg* 2005;16:749-59.

**How to cite this article:** Dhurat R, Sukesh MS. Principles and methods of preparation of platelet-rich plasma: A review and author's perspective. *J Cutan Aesthet Surg* 2014;7:189-97.

**Source of Support:** Nil. **Conflict of Interest:** None declared.

## Staying in touch with the journal

### 1) Table of Contents (TOC) email alert

Receive an email alert containing the TOC when a new complete issue of the journal is made available online. To register for TOC alerts go to [www.jcasonline.com/signup.asp](http://www.jcasonline.com/signup.asp).

### 2) RSS feeds

Really Simple Syndication (RSS) helps you to get alerts on new publication right on your desktop without going to the journal's website. You need a software (e.g. RSSReader, Feed Demon, FeedReader, My Yahoo!, NewsGator and NewzCrawler) to get advantage of this tool. RSS feeds can also be read through FireFox or Microsoft Outlook 2007. Once any of these small (and mostly free) software is installed, add [www.jcasonline.com/rssfeed.asp](http://www.jcasonline.com/rssfeed.asp) as one of the feeds.

Copyright of Journal of Cutaneous & Aesthetic Surgery is the property of Medknow Publications & Media Pvt. Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.